Trial of Psilocybin versus Escitalopram for Depression
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. METHODS: In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Patients were assigned in a 1:1 ratio to receive two separate doses of 25 mg of psilocybin 3 weeks apart plus 6 weeks of daily placebo (psilocybin group) or two separate doses of 1 mg of psilocybin 3 weeks apart plus 6 weeks of daily oral escitalopram (escitalopram group); all the patients received psychological support. The primary outcome was the change from baseline in the score on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16; scores range from 0 to 27, with higher scores indicating greater depression) at week 6. There were 16 secondary outcomes, including QIDS-SR-16 response (defined as a reduction in score of >50%) and QIDS-SR-16 remission (defined as a score of ≤5) at week 6. RESULTS: A total of 59 patients were enrolled; 30 were assigned to the psilocybin group and 29 to the escitalopram group. The mean scores on the QIDS-SR-16 at baseline were 14.5 in the psilocybin group and 16.4 in the escitalopram group. The mean (±SE) changes in the scores from baseline to week 6 were -8.0±1.0 points in the psilocybin group and -6.0±1.0 in the escitalopram group, for a between-group difference of 2.0 points (95% confidence interval [CI], -5.0 to 0.9) (P = 0.17). A QIDS-SR-16 response occurred in 70% of the patients in the psilocybin group and in 48% of those in the escitalopram group, for a between-group difference of 22 percentage points (95% CI, -3 to 48); QIDS-SR-16 remission occurred in 57% and 28%, respectively, for a between-group difference of 28 percentage points (95% CI, 2 to 54). Other secondary outcomes generally favored psilocybin over escitalopram, but the analyses were not corrected for multiple comparisons. The incidence of adverse events was similar in the trial groups. CONCLUSIONS: On the basis of the change in depression scores on the QIDS-SR-16 at week 6, this trial did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients. Secondary outcomes generally favored psilocybin over escitalopram, but the analyses of these outcomes lacked correction for multiple comparisons. Larger and longer trials are required to compare psilocybin with established antidepressants. (Funded by the Alexander Mosley Charitable Trust and Imperial College London's Centre for Psychedelic Research; ClinicalTrials.gov number, NCT03429075.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In two recent psilocybin clinical trials, ~95% of all volunteers were eliminated on the basis of exclusion criteria”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [8]
In the citing paper
“Amelioration of symptomatic depression in pilot studies of major depressive disorder, including those that compared psilocybin with escitalopram 8,9 and that investigated its use in treatment-resistant depression, 10 has suggested therapeutic potential for this agent.”
From Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (2022) · cites this paper as [9]
In the citing paper
“Studies have used inactive placebos (e.g., [17, 35]), active placebos whose effects considerably differ from the acute effects of serotonergic psychedelics (e.g., [15, 36, 37]), or doses of psilocybin presumably too low to maintain blinding (e.g., [38, 39])”
In the citing paper
“Contemporary clinical studies have involved one to three dosing sessions (e.g., [38, 39, 117])”
In the citing paper
“Research on MDD, anxiety and depressive symptoms associated with life-threatening cancer, and TRD showed the most robust evidence, supported by a non-randomized study 72 and several RCTs. 26,31-33,60,73-77”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [26]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Malhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Self-citationEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Cited by
Items 501–600 of 1,001
Psychedelic Therapy: A Primer for Primary Care Clinicians—Psilocybin
Tabaac, B. J., Shinozuka, K., Arenas, A., Beutler, B. D., Cherian, K. N., Evans, V. D., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001724 · Cited by 17
“71 Third, current treatment modalities require continued adherence in Medicaid populations, whose time on a health plan is an average of 10 months.”
BackgroundAtiq, M. A., Baker, M. R., Voort, J. L. V., Vargas, M. V., & Choi, D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06599-5 · Cited by 18
“…is that discrepancies in these associations exist between clinical trials, with three aforementioned studies finding no evidence of an association (Carhart-Harris et al. 2021; Slo-shower et al. 2023; von Rotz et al. 2023), although the reason for one may be the limited sample size and exploratory…”
Szafoni, S., Gręblowski, P., Grabowska, K., & Więckiewicz, G. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1406888 · Cited by 18
Psychedelics and Consciousness: Expanding the Horizons of Mind and Therapy
Zhang, M., Wang, Y., Gao, T., & Wang, X. (2024) · Research · doi:10.34133/research.0495 · Cited by 17
“…psychedelics have shown efficacy in treating a range of neuro-psychiatric conditions, such as depression, post-traumatic stress disorder, anxiety, and addiction, particularly in cases where conventional treatments like selective serotonin reuptake inhibitors (SSRIs) have failed [ 10 – 14 ].”
BackgroundHarnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy
Halman, A., Conyers, R. K., Moore, C., Khatri, D., Sarris, J. J., & Perkins, D. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3459 · Cited by 19
Marchi, M., Farina, R., Rachedi, K., Laonigro, F., Žuljević, M. F., Pingani, L., Ferrari, S., Somers, M., Boks, M. P., & Galeazzi, G. M. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241303594 · Cited by 23
“Interestingly, ketamine has also been studied for MDD, particularly in treat-ment-resistant patients, showing efficacy in reducing depressive symptoms and suicidal ideation (An et al., 2021; Bahji et al., 2021; Witt et al., 2020).”
InfluentialElfrink, S., & Bergin, L. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1528253 · Cited by 20
Toward a typology of hallucinogen users in the United States
Salas‐Wright, C. P., Hodges, J. C., Hai, A. H., Alsolami, A., & Vaughn, M. G. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109139 · Cited by 17
Non-sedative cortical EEG signatures of allopregnanolone and functional comparators
Lambert, P. M., Ni, R., Benz, A. M., Rensing, N. R., Wong, M., Zorumski, C. F., & Mennerick, S. J. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01450-x · Cited by 16
Kelly, D. F., Heinzerling, K. G., Sharma, A., Gowrinathan, S., Sergi, K., & Mallari, R. J. (2022) · Neurosurgery · doi:10.1227/neu.0000000000002275 · Cited by 17
Human behavioral pharmacology of psychedelics
Strickland, J. C., & Johnson, M. W. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2021.10.003 · Cited by 16
Schmitz, G. P., Chiu, Y.-T., König, G. M., Kostenis, E., Roth, B. L., & Herman, M. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.15.516655 · Cited by 23
Weiss, B., Sleep, C., Miller, J. D., & Campbell, W. K. (2023) · Journal of Personality Disorders · doi:10.1521/pedi.2023.37.2.131 · Cited by 15
Agrawal, R. G., Gillie, D. J., Mungenast, A. E., Chytil, M., Engel, S. R., Wu, M. C., Rasmussen, K., Salinas, E. O., & Olson, D. E. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00667 · Cited by 18
Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review
Fonseka, L. N., & Woo, B. K. P. (2023) · World Journal of Psychiatry · doi:10.5498/wjp.v13.i5.182 · Cited by 15
Carlisle, N. A., Dourron, H. M., MacCarthy, S., Zarrabi, A. J., & Hendricks, P. S. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2022.0018 · Cited by 17
Pilozzi, A. R., Foster, S. L., Mischoulon, D., Fava, M., & Huang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512513 · Cited by 17
Wong, S., Yu, A. Y., Fabiano, N., Finkelstein, O., Pasricha, A., Jones, B. D. M., Rosenblat, J. D., Blumberger, D. M., Mulsant, B. H., & Husain, M. I. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2251133 · Cited by 17
“…distress, and alcohol use disorder, with multiple clinical trials currently underway, there remain barriers to its clinical utility and scalability (Aday, Carhart-Harris, and Woolley 2023; Carhart-Harris et al. 2021; Johnson, Richards, and Griffiths 2008; Kiraga et al. 2022; Ross et al. 2016).”
Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders
Heresco‐Levy, U., & Lerer, B. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02312-8 · Cited by 15
“Recent studies with psilocybin suggest signi fi cant bene fi ts in major depressive disorder for 1-2 psilocybin (~25 mg) administration sessions [33, 34].”
Psychedelic-assisted therapy among sexual and gender minority communities
Hanshaw, B. D., Fusunyan, M. A., Anderson, C. T. M., & Turban, J. L. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00252-y · Cited by 15
Study protocol for “Psilocybin in patients with fibromyalgia: brain biomarkers of action”
Bornemann, J., Close, J. B., Ahmad, K., Barba, T., Godfrey, K., Macdonald, L., Erritzøe, D., Nutt, D. J., & Carhart-Harris, R. L. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1320780 · Cited by 16
Self-citationKinderlehrer, D. A. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s500337 · Cited by 18
Trauma under psychedelics: how psychoactive substances impact trauma processing
Netzer, O., Magal, N., Stern, Y., Polinsky, T., Gross, R., Admon, R., & Salomon, R. (2025) · World Psychiatry · doi:10.1002/wps.21363 · Cited by 20
The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice
Fleury, S., & Nautiyal, K. M. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03387-1 · Cited by 16
“Growing evidence supports their ef fi cacy in treating major depressive disorder (MDD) and other mood and anxiety disorders [3 – 8].”
Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?
Munafò, A., Arillotta, D., Mannaioni, G., Schifano, F., Bernardini, R., & Cantarella, G. (2022) · Pharmaceuticals · doi:10.3390/ph16010068 · Cited by 15
“The use of low-dose psychedelics as part of a potential active control condition represents a promising starting point to improve participant masking and balance treatment expectations among conditions [34,41].”
BackgroundA transdiagnostic meta-analysis of acute augmentations to psychological therapy
Nord, C. L., Longley, B. F., Dercon, Q., Phillips, V., Funk, J., Gormley, S., Knight, R., Smith, A., & Dalgleish, T. (2023) · Nature Mental Health · doi:10.1038/s44220-023-00048-6 · Cited by 16
Reducing the Harms of Nonclinical Psychedelics Use Through a Peer-Support Telephone Helpline
Pleet, M. M., White, J. T., Zamaria, J. A., & Yehuda, R. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2022.0017 · Cited by 16
Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT 2A receptor agonists
Sharp, T., & Ippolito, A. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70050 · Cited by 17
“Today, several Phase 2 clinical trials report convincing evidence of rapid-onset antidepressant effects of psilocybin , even in patients previously resistant to other treatments (Carhart-Harris et al., 2021; Goodwin et al., 2022; Raison et al., 2023).”
Hosein, M., Reid, M. J., Walser, S. A., Charney, S., Fonzo, G. A., Lewis, B. R., Yaden, D. B., Suppes, T. M., Cordner, Z. A., & Barrett, F. S. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103517 · Cited by 16
Florineth, G. A., Klima, I., Boeker, A. L., Catzeflis, P., Wopfner, A., Denier, N., Bracht, T., Adorjan, K., Pfammatter, M., Müller, F., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.54843 · Cited by 15
Schmid, Y., & Bershad, A. K. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.02.001 · Cited by 23
“…evidence suggesting efficacy of classical serotonergic psychedelics, including lysergic acid diethylamide (LSD) and psilocybin, in the treatment of depression (2–4), anxiety (due to life-threatening diseases) (5,10–12), alcohol use disorder (6), body dysmorphia (13), and anorexia nervosa (14).”
BackgroundAutism, youth suicide, and psychedelics: A review of the 21st century evidence
Chen, M., Su, T., Hsu, J.-W., & Tsai, S. (2024) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001150 · Cited by 16
“37 In brief, 59 patients with TRD were randomly assigned to either the oral psilocybin or the oral escitalopram (a selective serotonin-reuptake inhibitor) groups.”
InfluentialLess is more? A review of psilocybin microdosing
Savides, I. A., & Outhoff, K. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241278769 · Cited by 15
“…patients, TRD as well as obsessive-compulsive disorder (OCD) and substance use disorders including nicotine and alcohol (Bogenschutz et al., 2022; Carhart-Harris et al., 2016, 2021; Goodwin et al., 2023; Grob et al., 2011; Johnson et al., 2014; Kelmendi et al., 2022; Raison et al., 2023; Yu et…”
Mechanisms of psilocybin on the treatment of posttraumatic stress disorder
Choi, C. Q., Johnson, D. E., Chen-Li, D. C. J., & Rosenblat, J. D. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241286771 · Cited by 16
“Psilocybin acts on many of the same areas of the brain affected in patients with PTSD. Psilocybin usage was associated with reduced amygdala reactivity to negative stimuli measured on fMRI (Kraehenmann et al., 2015), decreased threat response, as well as to increased amygdala responsiveness to positive emotional stimu…”
InfluentialArias, H. R., Rudin, D., Luethi, D., Valenta, J., Leśniak, A., Czartoryska, Z., Olejarz‐Maciej, A., Doroż-Płonka, A., Manetti, D., Deurwaerdère, P. D., et al. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111217 · Cited by 14
Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management
Strand, N. H., Whitney, M. A., Johnson, B. W., Dunn, T., Attanti, S., Maloney, J. A., Misra, L., Gomez, D., Viswanath, O., Emami, E., et al. (2025) · Current Pain and Headache Reports · doi:10.1007/s11916-024-01353-0 · Cited by 15
“Recent randomized controlled trials (RCTs) have reported excellent safety and efficacy results [110 , 111].”
What is Psychological Support in the Context of Psychedelic Clinical Trials?
Richard, J., & Levine, M. A. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0026 · Cited by 15
“6,8,15,28 Whether or not there is adequate fi delity with regards to how psychological support as implemented resembles the claims made by the investigators in the procedures for these trials, they are descriptively consistent.”
Benchmarking macaque brain gene expression for horizontal and vertical translation
Luppi, A. I., Liu, Z.-Q., Hansen, J. Y., Cofre, R., Niu, M., Kuzmin, E., Froudist-Walsh, S., Palomero-Gallagher, N., & Misic, B. (2025) · Science Advances · doi:10.1126/sciadv.ads6967 · Cited by 14
Adebo, M., Bonnet, M., Laouej, O., Defaix, C., McGowan, J. C., Butlen‐Ducuing, F., David, D. J. P., Poupon, E., Tritschler, L., & Gardier, A. M. (2025) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.70038 · Cited by 14
Concomitant use of antidepressants and classic psychedelics: A scoping review
Tap, S. C., Thomas, K. L. H., Páleníček, T., Stenbæk, D. S., Oliveira-Maia, A. J., van Dalfsen, J. H., & Schoevers, R. A. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251368360 · Cited by 16
“…psyche-delics, patients enrolled in most contemporary clinical trials are typically required to discontinue ADs at least 2 weeks before drug administration (Carhart-Harris et al., 2021; Davis et al., 2021; Goodwin et al., 2022; Raison et al., 2023; Sloshower et al., 2023; von Rotz et al., 2023).”
Dementia and COVID-19: A Case Report and Literature Review on Pain Management
Scuteri, D., Contrada, M., Tonin, P., Corasaniti, M. T., Nicotera, P., & Bagetta, G. (2022) · Pharmaceuticals · doi:10.3390/ph15020199 · Cited by 15
“Therefore, it is fundamental to avoid the unnecessary and harmful use of antipsychotics and antidepressants; on the other hand, the novel rapid-acting antidepressants are worthy of investigation [57].”
BackgroundDisruptive innovation in psychiatry
Sarris, J. J. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14764 · Cited by 14
“Promising disruptive treatment approaches include the use of (1) psychedelic-based medicines, including the development of psychedelic drug analogues (with further research into standardized psychoactive plant-based medicines, such as cannabinoid therapies), (2) microbiome-altering therapies, (3) improved drug deliver…”
BackgroundPhysical Disability and Psychedelic Therapies: An Agenda for Inclusive Research and Practice
Mintz, K. T., Gammer, B., Khan, A. J., Shaub, G., Levine, S., & Sisti, D. A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.914458 · Cited by 14
“Psilocybin is currently under investigation for treating a range of conditions from treatment-resistant depression (3, 4) (TRD) to phantom limb pain (5).”
Kuburi, S., Passa, A.-M. D., Tassone, V. K., Mahmood, R., Lalovic, A., Ladha, K. S., Dunlop, K., Rizvi, S. J., Demchenko, I., & Bhat, V. (2022) · Chronic Stress · doi:10.1177/24705470221115342 · Cited by 18
Longo, M. S. C., Bienemann, B., Multedo, M., Negreiros, M. A., Schenberg, E. E., & Mograbi, D. C. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2112788 · Cited by 15
Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies
Weleff, J., Akiki, T. J., & Barnett, B. S. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2133757 · Cited by 14
The experience of ‘treatment‐resistant’ depression: A qualitative meta‐synthesis
Crowe, M., Manuel, J., Carlyle, D., Thwaites, B., & Lacey, C. J. (2023) · International Journal of Mental Health Nursing · doi:10.1111/inm.13107 · Cited by 16
Unblinding and demand characteristics in the treatment of depression.
Goodwin, G., Croal, M., Marwood, L., & Malievskaia, E. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.02.030 · Cited by 12
In silico characterization of the psilocybin biosynthesis pathway
Irvine, W. A., Tyler, M. W., & Delgoda, R. (2023) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2023.107854 · Cited by 14
Cognitive liberty and the psychedelic humanities
Romero, O. S. G. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1128996 · Cited by 14
Langlitz, N. (2023) · Anthropology Today · doi:10.1111/1467-8322.12813 · Cited by 16
Rossi, G. N., Rocha, J. M., Osório, F. D. L., Bouso, J. C., Oña, G., Silveira, G. D. O., Yonamine, M., Bertozi, G., Crevelin, E. J., Queiroz, M. E. C., et al. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001691 · Cited by 13
Alnsasra, H., Khalil, F. M., Perue, R. K., & Azab, A. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411270 · Cited by 17
Promising new pharmacological targets for depression: The search for efficacy
Tsugiyama, L. E., de Moraes, R. C. M., Moraes, Y. A. C., & de Oliveira, J. F. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103804 · Cited by 16
Sandbrink, J. D., Johnson, K., Gill, M., Yaden, D. B., Savulescu, J., Hannikainen, I. R., & Earp, B. D. (2024) · AJOB Neuroscience · doi:10.1080/21507740.2024.2303154 · Cited by 16
“While recreational use of psilocybin is federally prohibited, the FDA recently granted psilocybin “breakthrough therapy status” for use in MDD and treatment-resistant depression, facilitating clinical research.”
BackgroundInfluentialWiley, J. F., & Bei, B. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2108082 · Cited by 14
Self-citationVanderijst, L., Hever, F., Buot, A., Dauré, C., Benoit, J., Hanak, C., Veeser, J., Morgiève, M., Campanella, S., Kornreich, C., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05502-y · Cited by 13
“…differ from the acute effects of serotonergic psychedelics (e.g., [15, 36, 37]), or doses of psilocybin presumably too low to maintain blinding (e.g., [38, 39]), leading to a general call for more effective active placebo conditions and a systematic reporting of blinding efficacy [32–34].”
BackgroundScala, M., Fabbri, C., Fusar-Poli, P., Di Lorenzo, G., Ferrara, M., Amerio, A., Fusar-Poli, L., Pichiecchio, A., Asteggiano, C., Menchetti, M., et al. (2024) · CNS Spectrums · doi:10.1017/s1092852924002268 · Cited by 13
“26 In terms of safety, psilocybin was better tolerated than escitalopram, 26 although the latter contributed to mitigating psilocybin-induced acute autonomic adverse events in the study arm evaluating the response to psilocybin after pretreatment with escitalopram.”
InfluentialBarnett (2024) · doi:10.1089/psymed.2023.0010 · Cited by 13
Utility of preclinical models in the study of psilocybin – A comprehensive review
Pedicini, M., & Cordner, Z. A. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105046 · Cited by 15
G protein-coupled receptors as targets for transformative neuropsychiatric therapeutics
Schmitz, G. P., & Roth, B. L. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00397.2022 · Cited by 13
Molecular insights into GPCR mechanisms for drugs of abuse
Sánchez-Reyes, O. B., Zilberg, G., McCorvy, J. D., & Wacker, D. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105176 · Cited by 13
Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects
McCulloch, D. E.-W., Liechti, M. E., Kuypers, K. P. C., Nutt, D. J., Lundberg, J., Stenbæk, D. S., Goodwin, G. M., Gründer, G., Butlen‐Ducuing, F., Haberkamp, M., et al. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.103938 · Cited by 17
Self-citationPsychedelic Therapy: A Primer for Primary Care Clinicians—Historical Perspective and Overview
Tabaac, B. J., Shinozuka, K., Arenas, A., Beutler, B. D., Cherian, K. N., Evans, V. D., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001727 · Cited by 15
“15,17,26 However, subsequent phase II studies that enrolled up to 233 patients found that only 25% – 29% of participants experienced remission from depression.”
BackgroundMagic of the Mushrooms: Effects of Psilocybin Decriminalization
Bhave, A. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2376755 · Cited by 15
Nicholas, C. R. N., Banks, M. I., Lennertz, R. C., Wenthur, C. J., Krause, B. M., Riedner, B. A., Smith, R., Hutson, P. R., Sauder, C. J., Dunne, J. D., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03059-8 · Cited by 19
“Here, we identi fi ed a dosing strategy for midazolam that when co-administered with psilocybin produced minimal sedation and allowed the occurrence of an acute psychedelic experience comparable to normative data but that appeared suf fi cient to attenuate memory of the psychedelic experience.”
BackgroundMethodEvaluating the potential for psilocybin as a treatment for post-traumatic stress disorder
Miller, C., & Zoladz, P. R. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002237 · Cited by 13
What should constitute a control condition in psychedelic drug trials?
Colloca, L., & Fava, M. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00321-2 · Cited by 17
“Recently, Szigeti and colleagues reported on a pretreatment expectation measurement in relation to the outcome of a psilocybin versus escitalopram study 85 .”
How to Make Psychedelic-Assisted Therapy Safer
Villiger, D. (2024) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180124000604 · Cited by 14
Psilocybin and Hallucinogenic Mushrooms
Fradet, M., Kelly, C. M., Donnelly, A. J., & Suppes, T. M. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009585330.004 · Cited by 13
Catalyst for change: Psilocybin’s antidepressant mechanisms—A systematic review
Liebnau, J., Betzler, F., & Kerber, A. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811241312866 · Cited by 14
Pharmacological Monotherapy for Depressive Disorders: Current and Future—A Narrative Review
Gao, K., Oruc, E. B., & Koparal, B. (2025) · Medicina · doi:10.3390/medicina61040558 · Cited by 14
“Several small-scale studies have demonstrated the efficacy of psilocybin in the treatment of depression and TRD [88,90,91].”
Brouns, E. J., Ekins, T. G., & Ahmed, O. J. (2025) · Psychedelics. · doi:10.61373/pp025r.0002 · Cited by 16
Psychedelic neuroplasticity of cortical neurons lacking 5-HT2A receptors
Ekins, T. G., Rybicki-Kler, C., Deng, T., Brooks, I. A. W., Jedrasiak‐Cape, I., Donoho, E., & Ahmed, O. J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03257-w · Cited by 22
van den Berg, M., Magaraggia, I., Schreiber, R., Hillhouse, T. M., & Porter, J. H. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06106-8 · Cited by 13
“, 16-item Quick Inventory of Depressive Symptomatology–Self-Report; QIDS-SR-16), it was more effective on secondary outcomes and better tolerated (Carhart-Harris et al. 2021).”
MethodPsychedelic assisted therapy for major depressive disorder: Recent work and clinical directions
McCartney, A., McGovern, H. T., & Foe, A. D. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00211 · Cited by 13
“However, such research was often not carefully monitored, with subjects given different doses, and little consistency in research protocol (Nutt & Carhart-Harris, 2021).”
BackgroundInfluentialMeccia, J., Lopez, J., & Bagot, R. C. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06297-0 · Cited by 14
“These findings were recently replicated in cohorts of patients with MDD, with antidepressant effects enduring as long as 12 months after psilocybin therapy sessions (Carhart-Harris et al. 2021; Davis et al. 2021; Gukasyan et al. 2022).”
BackgroundBălăeţ, M., Trender, W. R., Hellyer, P. J., & Hampshire, A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1184681 · Cited by 14
“In particular, psychedelics have recently received a tremendous increase in positive attention relative to other drugs, with therapeutic effects noted in clinical studies conducted with patients suffering from depression (18), anxiety (19), alcoholism (23), tobacco addiction (24) and obsessive–compulsive disorder (25).”
BackgroundThe Relationship Between Naturalistic Psychedelic Use and Clinical Care in Canada
Glynos, N. G., Kruger, D. J., Kolbman, N., Boehnke, K. F., & Lucas, P. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2242353 · Cited by 15
“Indeed, psilocybin-assisted therapy shows potential for treating major depressive disorder (Carhart-Harris et al. 2021; Davis et al. 2021; Goodwin et al. 2022), as well as alcohol (Bogenschutz et al. 2015, 2022) and tobacco dependence (Johnson et al. 2014; Johnson, Garcia-Romeu, and Griffiths 2016).”
BackgroundSARS-CoV-2 Psychiatric Sequelae: A Review of Neuroendocrine Mechanisms and Therapeutic Strategies
Hornick, M. G., Olson, M. E., & Jadhav, A. L. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab069 · Cited by 14
“Finally, the recent finding that there is no significant difference in the anti-depressive effects of psilocybin and escitalopram in a phase 2, double-blind, randomized, controlled clinical trial in patients with chronic, moderate-to-severe depression highlights an opportunity for psychedelics in long-haul COVID-19 ps…”
BackgroundPrimum non nocere: The onus to characterize the potential harms of psychedelic treatment
Ghaznavi, S., Ruskin, J. N., Haggerty, S. J., King, F., & Rosenbaum, J. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230914 · Cited by 12
Psychedelic medicines for mood disorders: current evidence and clinical considerations.
Sarris, J. J., Rubiano, D. P., Day, K., Coelho, N. L. G., & Perkins, D. (2022) · PubMed · doi:10.1097/yco.0000000000000759 · Cited by 12
The potential of psilocybin use to enhance well-being in healthy individuals – A scoping review
Wiepking, L., de Bruin, E. J., & Ghiţă, A. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00244 · Cited by 14
Krupp, K. T., Yaeger, J. D. W., Ledesma, L. J., Withanage, M. H. H., Gale, J., Howe, C. B., Allen, T. J., Sathyanesan, M., Newton, S. S., & Summers, C. H. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109949 · Cited by 13
Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD)
Olivier, B., & Olivier, J. D. A. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-4402-2_3 · Cited by 13
Classical psychedelics’ action on brain monoaminergic systems
Butler, J. J., Ricci, D., Aman, C., Beyeler, A., & Deurwaerdère, P. D. (2024) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2024.106669 · Cited by 12
Neuroprotective effects of psilocybin in a rat model of stroke
Yu, S., Wu, K., Wang, Y.-S., Bae, E., Chianelli, F., Bambakidis, N. C., & Wang, Y. (2024) · BMC Neuroscience · doi:10.1186/s12868-024-00903-x · Cited by 16
Jones, G. M., Lowe, M. X., Nayak, S. M., Sepeda, N. D., Kettner, H., Carhart-Harris, R. L., Jackson, H., & Garcia‐Romeu, A. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.10.058 · Cited by 14
Self-citationBeyond psychedelics: set and setting in general psychiatric practice
Kozak, Z., & Miller, C. W. T. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2419662 · Cited by 14
“…factors for treatment response including high levels of education, gainful employment, and enough financial stability to be able to participate in lengthy clinical trials (Carhart-Harris et al., 2016; Carhart-Harris et al., 2021; Davis et al., 2021; Ross et al., 2016; Thrul & Garcia-Romeu, 2021).”
Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review
Erkizia-Santamaría, I., Horrillo, I., Meana, J. J., & Ortega, J. E. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111249 · Cited by 13
Yaden, D. B., Graziosi, M., Owen, A. M., Agin-Liebes, G., Aaronson, S. T., Allen, K. E., Barrett, F. S., Bogenschutz, M. P., Carhart-Harris, R. L., Ching, T. H. W., et al. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0019 · Cited by 13
“25 Expectancy was assessed in terms of ef fi cacy-related expectancy (i.e., “ how much improvement in your mental health do you think will occur?”
Self-citationArgento, E., Christie, D., Mackay, L., Callon, C., & Walsh, Z. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.716593 · Cited by 13
Kvam, T.-M., Goksøyr, I. W., Stewart, L. H., Repantis, D., Røssberg, J. I., & Andreassen, O. A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.954388 · Cited by 13
“However, secondary outcome measures generally favored psilocybin (16).”
BackgroundGarcía‐Gutiérrez, M. S., Navarro, D., Austrich-Olivares, A., & Manzanares, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1171646 · Cited by 16
“This should be further explored due to the emerging interest in 5-HT2A agonists for treating anxiety and depression, such as the LSD-like psychedelic drugs that acting as 5-HT2A agonists display rapid antidepressant effects related to their neuroplastic actions (Corne and Mongeau, 2019; Carhart-Harris et al., 2021; Ta…”
BackgroundGao, B., Qu, Y.-C., Cai, M., Zhang, Y.-Y., Lu, H., Li, H.-X., Tang, Y., & Shen, H. (2023) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2023.06.006 · Cited by 12
Social Psychopharmacology: Novel Approaches to Treat Deficits in Social Motivation in Schizophrenia
Bershad, A. K., & de Wit, H. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad094 · Cited by 12
Anderson, T. L., Keady, J. V., Songrady, J. C., Tavakoli, N. S., Asadipooya, A., Neeley, R. E., Turner, J. R., & Ortinski, P. I. (2024) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2024.102660 · Cited by 16
Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa
Rodan, S.-C., Aouad, P., McGregor, I. S., & Maguire, S. (2021) · OBM Neurobiology · doi:10.21926/obm.neurobiol.2102102 · Cited by 13
“A clinically significant antidepressant effect was reported in 70% of those allocated in the psilocybin group, compared to 47% with escitalopram and remission occurred in 57% and 28%, participants respectively [107].”
BackgroundResultThe Potential Role of Serotonergic Hallucinogens in Depression Treatment
Psiuk, D., Nowak, E., Cholewa, K., Łopuszańska, U., & Samardakiewicz, M. (2021) · Life · doi:10.3390/life11080765 · Cited by 16
“, 2021 [32] 30 psilocybin 25 mg feeling jittery: 7%, sleep disorder: 3% headache: 67%, migraine: 10% palpitations: 3% nausea: 27%, vomiting: 7%, diarrhea: 3% fatigue: 7%”
BackgroundResultInfluentialA whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production.
McKernan, K. J., Kane, L. T., Helbert, Y., Zhang, L., Houde, N., & McLaughlin, S. (2021) · F1000Research · doi:10.12688/f1000research.55301.1 · Cited by 13
“Psilocybin has also been shown to be a safe alternative to traditional selective serotonin re-uptake inhibitors (SSRIs) for the treatment of depression (Griffiths et al. 2016; Ross et al. 2016; Bogenschutz et al. 2018; Carhart-Harris et al. 2021; Davis et al. 2021).”
Background
Metadata
- Authors
- Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J.
- Affiliations
- Imperial College London (GB)
- From the Centre for Psychedelic Research, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-04-15
- Volume
- 384
- Issue
- 15
- Pages
- 1402-1411
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3156937150
- Cited by
- 1,391
- References
- 26
- Citations by year
- 2026: 200 · 2025: 278 · 2024: 287 · 2023: 284 · 2022: 247 · 2021: 92
- FWCI
- 154.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alex Mosley Charitable Trust (NA)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- psilocybin, escitalopram, major depressive disorder, antidepressant efficacy, psychedelic therapy, selective serotonin reuptake inhibitors, depression remission, treatment-resistant depression, psychological support, hallucinations, dissociation, synesthesia, anxiety disorders
- MeSH terms
- Adult, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Female, Hallucinogens, Humans, Male, Middle Aged, Psilocybin, Surveys and Questionnaires, Citalopram, Antidepressive Agents, Second-Generation, Young Adult, Self Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.